Literature DB >> 32142713

Moving on from the failed HIV vaccine clinical trial.

Paul Adepoju.   

Abstract

Year:  2020        PMID： 32142713     DOI： 10.1016/S2352-3018(20)30047-3

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  7 in total

1.  Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers.

Authors:  Frank Msafiri; Agricola Joachim; Kathrin Held; Yuka Nadai; Raquel Matavele Chissumba; Christof Geldmacher; Said Aboud; Wolfgang Stöhr; Edna Viegas; Arne Kroidl; Muhammad Bakari; Patricia J Munseri; Britta Wahren; Eric Sandström; Merlin L Robb; Sheena McCormack; Sarah Joseph; Ilesh Jani; Guido Ferrari; Mangala Rao; Gunnel Biberfeld; Eligius Lyamuya; Charlotta Nilsson
Journal:  Microorganisms       Date:  2020-11-04

2.  STAT3 determines IL-4 signalling outcomes in naïve T cells.

Authors:  Lachlan P Deimel; Zheyi Li; Sreeja Roy; Charani Ranasinghe
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

3.  Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques.

Authors:  Z Li; M Khanna; S L Grimley; P Ellenberg; C A Gonelli; Wen Shi Lee; T H Amarasena; A D Kelleher; D F J Purcell; S J Kent; C Ranasinghe
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

4.  Exosome-mediated stable epigenetic repression of HIV-1.

Authors:  Surya Shrivastava; Roslyn M Ray; Leo Holguin; Lilliana Echavarria; Nicole Grepo; Tristan A Scott; John Burnett; Kevin V Morris
Journal:  Nat Commun       Date:  2021-09-20       Impact factor: 14.919

5.  Milk exosomes elicit a potent anti-viral activity against dengue virus.

Authors:  Vengala Rao Yenuganti; Sumbul Afroz; Nooruddin Khan; Rafiq Ahmad Khan; Chandrima Bharadwaj; Deepti Kailash Nabariya; Nagaraj Nayak; Madhuri Subbiah; Kumaraswami Chintala; Sharmistha Banerjee; Pallu Reddanna
Journal:  J Nanobiotechnology       Date:  2022-07-06       Impact factor: 9.429

6.  A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.

Authors:  Adonis A Rubio; Maria V Filsinger Interrante; Benjamin N Bell; Clayton L Brown; Theodora U J Bruun; Celia C LaBranche; David C Montefiori; Peter S Kim
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

7.  Global and Regional Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A Modeling Study.

Authors:  Ramyiadarsini Elangovan; Michael Jenks; Jason Yun; Leslie Dickson-Tetteh; Shona Kirtley; Joris Hemelaar
Journal:  Front Microbiol       Date:  2021-07-15       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.